Psychedelics in Therapy and Policy: The US Renaissance and a Trump Executive Order

The podcast examines the current resurgence of psychedelic medicines, the scientific evidence behind drugs like psilocybin, MDMA, ketamine and ibogaine, and the political and regulatory moves around them. It highlights how research, therapy, and policy intersect as the US contends with access, safety, and the pace of drug approvals.

• Executive action aims to accelerate access to psychedelic therapies and fund ibogaine research.
• Key figures and networks around psychedelics, including RFK Jr, Joe Rogan, and Brian Hubbard, influence the policy landscape.
• Debates continue over how much therapy versus medicine drives outcomes in psychedelic treatments.
• Questions remain about safety, at-home use, and how top-down policy will interact with clinical trials.

Overview

In the podcast, Scientific American editor Rachel Feltman and science journalist Jane C. Hu explore the renewed interest in psychedelic medicines, their potential for treating conditions such as depression PTSD and substance use disorders, and the regulatory and political dynamics shaping access. The conversation covers the therapeutic evidence for psilocybin and MDMA, the growing use of ketamine, and the resurgence of ibogaine, while also unpacking the implications of a recent executive order intended to accelerate access to psychedelic drugs in the United States.

Context and Momentum for psychedelic research

The discussion situates the psychedelic revival in a historical arc. Psychedelics fell out of favor in the late 1960s due to regulation and public opinion, temporarily stalling promising findings. Johns Hopkins and other institutions reignited regulatory approvals around the turn of the century, catalyzing renewed exploration of MDMA, psilocybin and other compounds as potential medicines for PTSD, depression and related conditions. Hu notes that this revival has coincided with policy experiments, including Oregon and Colorado programs that permit supervised use and research within state frameworks. The podcast also mentions an FDA investigational new drug designation landscape that has grown more permissive as data accumulate in supportive directions.

Key compounds and the science behind the renaissance

The guests discuss several psychedelic families, their evidence base, and the practical challenges of translating research into clinical practice:

Psilocybin and MDMA

Evidence has accumulated suggesting benefits for depression, anxiety and PTSD in particular, with some regulatory attention from the FDA via investigational designations. A notable recent moment was a company called Lycos, now renamed Resilient, submitting an application to the FDA to obtain approval for MDMA as a medicine; the application ultimately did not succeed, but the trajectory remains a focal point for policymakers and researchers. The dialogue also underscores that the therapeutic value appears in large part from the combination of a drug with supportive psychotherapy, and that disentangling the drug's pharmacology from the therapy is scientifically challenging.

Ketamine

Ketamine stands out as one of the most accessible therapeutics in this space, widely used off-label and available in various formats, including at-home use. The safety and mechanism questions are ongoing, particularly for self-administered or unsupervised use, which contrast with more controlled clinical settings. The conversation emphasizes that therapy around ketamine may be crucial for optimizing results, though the field must still resolve safety and standardization questions.

Ibogaine

Ibogaine has experienced a resurgence tied to veterans' mental health and addiction treatment. Hu explains that many researchers remained cautious due to risks, notably heart-related complications, and the intense, long-lasting subjective experience ibogaine can produce. Nevertheless, advocates argue for expanding US research to reduce reliance on out-of-country retreats, while researchers stress careful risk management and incremental clinical evaluation.

The policy landscape: Executive action and influence

The episode centers on an April executive order signed by President Trump that aims to accelerate access to psychedelics and expand research, including a focus on ibogaine. The order is presented as a symbolic and practical push, aided by a network of advocates within the administration. Joins the conversation with Joe Rogan, who has been a conduit for psychedelic advocates, and Brian Hubbard, who has lobbied for increased ibogaine research. Hu recounts that Rogan’s text to the president helped catalyze this policy moment, illustrating how advocacy channels and media platforms can interact with governance in this space.

The executive order also covers a funding dimension: set aside $50 million to support state-level psychedelic trials and ibogaine research, partly aimed at aligning with Texas's own commitments. An additional policy mechanism discussed is an FDA voucher program that can accelerate the drug approval timeline from about a year to potentially as short as a month. Hu notes that some researchers worry about a top‑down signal from the White House potentially biasing FDA decision-making, highlighting a tension between expediency and regulatory rigor.

What this means for researchers, patients and the public

For researchers, the immediate substantive impact on psychedelic research may be limited, but the policy climate can influence funding opportunities and the regulatory environment in which trials operate. The ibogaine provisions could catalyze new research pathways, while the voucher program may compress timelines for certain psychedelic medicines. The broader questions concern safety, the role of therapy, and the ethics and governance of accelerating access to powerful psychedelic experiences. Critics press for more rigorous dissection of the therapeutic contributions of the therapy component versus the pharmacology of the drug, and for robust safety measures as access expands to supervised and unsupervised settings alike.

Looking forward

The podcast suggests a cautiously optimistic trajectory: more states may pursue psychedelic trials, and ibogaine could enter earlier stages of U.S. research if matching funds and regulatory support persist. At the same time, the science community calls for careful, standardized approaches to accompanying therapy, clearer safety protocols, and ongoing evaluation of outcomes to ensure that expanded access translates into real patient benefit without compromising safety or scientific integrity. The episode closes by underscoring that this is a rapidly evolving field where medicine, therapy, policy, and culture intersect in important ways, and where watchdogs and advocates alike will continue to watch how treatments, regulations, and access expand together.